We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00877045
First Posted: April 7, 2009
Last Update Posted: August 4, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Pfizer
Information provided by:
SCRI Development Innovations, LLC
  Purpose
This is a retrospective medical record abstraction to evaluate the patterns of care for Gastrointestinal stromal tumors (GIST) in the community setting. Patient demographics and characteristics along with the treatments received will be described. Investigators will establish the percentage of patients who undergo surgery, the percentage of patients who are treated with kinase inhibitors as well as in what setting (adjuvant or metastatic) as well as the duration of therapy. Physician information will also be collected to assess for differences in treatment based on physician or geographical differences.

Condition
Gastrointestinal Stromal Tumors

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting

Resource links provided by NLM:


Further study details as provided by SCRI Development Innovations, LLC:

Enrollment: 200
Study Start Date: January 2008
Study Completion Date: February 2009
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients diagnosed with GIST based on ICD-9 code from January 2005 to present will be eligible. This will include current active patients as well as patients who have expired and have medical chart available. Estimate reviewing approximately 300 charts total.
Criteria

Inclusion Criteria:

  • Patients diagnosed with GIST based on ICD-9 code from January 2005 to present will be eligible. This will include current active patients as well as patients who have expired and have medical chart available.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00877045


Locations
United States, Florida
Florida Cancer Specialists
Fort Myers, Florida, United States, 33901
United States, Georgia
Georgia Cancer Specialists
Atlanta, Georgia, United States, 30341
United States, Tennessee
Chattanooga Oncology Hematology Associates
Chattanooga, Tennessee, United States, 37404
Tennessee Oncology, PLLC
Nashville, Tennessee, United States, 37023
United States, Virginia
Virginia Cancer Institute
Richmond, Virginia, United States, 23235
Sponsors and Collaborators
SCRI Development Innovations, LLC
Pfizer
Investigators
Study Chair: Jeffrey F Patton, M.D. SCRI Development Innovations, LLC
  More Information

Responsible Party: Jeffrey F. Patton, M.D., SCRI Oncology Research Consortium
ClinicalTrials.gov Identifier: NCT00877045     History of Changes
Other Study ID Numbers: SCRI OUTCOMES 01
First Submitted: April 3, 2009
First Posted: April 7, 2009
Last Update Posted: August 4, 2010
Last Verified: August 2010

Keywords provided by SCRI Development Innovations, LLC:
Gastrointestinal Stromal Tumors
GIST
tyrosine kinase inhibitors
Imatinib
Gleevec
Suntinib
Sutent

Additional relevant MeSH terms:
Gastrointestinal Stromal Tumors
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases